Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Antidepressant (1) ·
Anxiolytic (1) ·
Dual orexin receptor antagonist (DORA) (1) ·
Norepinephrine-dopamine reuptake inhibitor (NDRI) (1) ·
SNRI (1) ·
the first approved (1) ·
wake-promoting agent (1) ·
[[:Category:Aminopenicillins|Aminopenicillin]] (1) ·
[[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (1) ·
[[:Category:Penicillins|Penicillin]] (1)
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) ·
Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
'"`UNIQ--vote-00000199-QINU`"' Extends ampicillin's spectrum with better oral bioavailability. Susceptible to β-lactamases; clavulanate co-administration restores activity against many resistant organisms'"`UNIQ--ref-0000019A-QINU`"'. (1)
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) ·
'"`UNIQ--vote-0000019B-QINU`"', '"`UNIQ--vote-0000019C-QINU`"', '"`UNIQ--vote-0000019D-QINU`"', '"`UNIQ--vote-0000019E-QINU`"', '"`UNIQ--vote-0000019F-QINU`"', '"`UNIQ--vote-000001A0-QINU`"' (1)
None (1) ·
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) ·
500 mg PO TID or 875 mg PO BID for most indications; 80-90 mg/kg/d divided BID in pediatric otitis media (1) ·
Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.


